000			03218cam a2200325 a 4500
003			EG-GiCUC
008			160306s2015 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.23.M.Sc.2015.Ab.P
100	0		_aAbha Ali Abdullah Mohammed
245	1	0	_aPrediction survival of Egyptian patients with advanced gastrointestinal malignancies using the Chuang {u2018}s prognostic score / _cAbha Ali Abdullah Mohammed ; Supervised Omar Alfarouk Zaki , Amr Yehia Sakr , Dina Ezz Eldain Farag
246	1	5	_aتوقع بقاء مرضى سرطان الجهاز الهضمي المتقدم المصريين باستخدام نقاط تشوانج التكهني
260			_aCairo : _bAbha Ali Abdullah Mohammed , _c2015
300			_a79 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology (Clinical)
520			_aBackground and aim:With the increasing number of agents active against cancer, advanced cancer patients including metastatic colorectal cancer (MCC) patients may continue receiving palliative systemic anticancer therapy (PSAT) near the end-of-life. Validated palliative prognostic models may be helpful in identifying MCC patients with limited survival who are unlikely to benefit from PSAT. One of these models in the Chuang{u2019}s prognostic score (CPS) which was developed to predict survival in terminal cancer patients.Methods:The CPS was prospectively assessed in 39 patients with MCC who were receiving PSAT. It is based on eight items: ascites, edema, cognitive impairment, liver and lung metastases, performance status, tiredness and weight loss. The total CPS score ranges from 0 to 8.5 with the higher score indicating worse prognosis.Results:For the whole group of patients, the median survival from the date of CPS assessment was 103 days (95%CI: 75-131) and the median CPS score was 4.5 (range: 2 {u2013} 8). Patients were divided into two groups using a CPS cutoff socre of 5, group 1 with a CPS score {u2264}5 and group 2 with a CPS score >5. Group 1 patients had a significantly (p=0.014) longer median survival of 149 days (95%CI: 77-221) in comparison to group 2 patients who had a median survival of 61 days (95%CI: 35-87). Using the same cutoff score, 3-month mortality was predicted with a positive predictive value of 71%, a negative predictive value of 76%, a sensitivity of 63%, a specificity of 83% and an overall accuracy of 74%.Conclusions:The CPS may be useful in identifying MCC patients with relatively shorter survival who are unlikely to benefit from continuing PSAT. Further studies to explore the role of the CPS and other palliative prognostic models in predicting survival in incurable cancer patients receiving PSAT are needed
530			_aIssued also as CD
653		4	_aColorectal cancer
653		4	_aMetastases
653		4	_aPalliative systemic anticancer therapy
700	0		_aAmr Yehia Sakr , _eSupervisor
700	0		_aDina Ezz Eldain Farag , _eSupervisor
700	0		_aOmar Alfarouk Zaki , _eSupervisor
905			_aEnas _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c55359 _d55359